Skip to main content
URMC / Alzheimers Care

AD-CARE: Alzheimer's Disease Care, Research and Education Program


Leqembi (lecanemab) was granted full FDA approval for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia on July 6, 2023. While this is an exciting step forward in the treatment of Alzheimer’s disease, this medication may not be appropriate for everyone with these diagnoses. If you are interested in finding out if Leqembi (lecanemab) is appropriate for you or your family member, we encourage you to speak with your current Memory Care provider. If you are interested in finding out about clinical trial opportunities in Alzheimer’s disease, contact us at AD-CARE at 585-602-5200.


Advancement of clinical research is a fundamental mission of the AD-CARE program.  We participate in a number of national and international studies that focus on different aspects of Alzheimer's Disease.

Specialists who have expertise in dementia treatment and research direct the day-to-day activities of our clinical studies.

We conduct studies concerning:

  • Prevention of Alzheimer's Disease
  • Early memory problems or cognitive impairment
  • Diagnostic tools used for Alzheimer's Disease
  • Behavioral disturbances in persons with Alzheimer's Disease


Lab processing

Forget-Me-Not Fund

Help support Alzheimer's Disease clinical research in the Rochester area by making a donation to the Forget-Me-Not Fund.